人民财讯1月12日电，天益医疗（301097）1月12日公告，公司拟以6000万元—1.2亿元回购股份，用于 实施股权激励或员工持股计划，回购价格不超过65元/股。 ...

格隆汇1月12日丨天益医疗(301097.SZ)公布，拟在本次回购价格上限65元/股（含）的条件下，按照本次 回购资金总额上限12,000万元（含）测算，预计可回购股份总数为184.6154万股，约占公司当前总股本 的3.13%；按照本次回购资金总额下限6,000万元（含）测算，预计可回购股份总数为92.3077万股，约 占公司当前总股本的1.57%。用于实施股权激励或员工持股计划，若公司未能在股份回购完成后的36个 月内用于上述用途，未使用部分将予以注销。 ...

证券代码：301097 证券简称：天益医疗 公告编号：2026-004 宁波天益医疗器械股份有限公司 关于调整为全资孙公司提供担保额度的公告 具体内容详见公司于 2025 年 3 月 19 日在在中国证监会指定创业板信息披露 网站巨潮资讯网上披露的《第三届董事会第二十二次会议决议公告》（公告编号： 2025-016）、《关于为全资孙公司提供担保的公告》（公告编号：2025-017）。 （二）本次调整为全资孙公司提供担保额度的情况 考虑到公司的实际业务需要，公司拟在第三届董事会第二十二次会议审议通 过的《关于为全资孙公司提供担保的议案》的基础上，将为全资孙公司提供担保 的额度整体调增 1 亿元人民币，具体情况如下： | | | 调整前预 | 调整后预 | 公告日担 | 公告日可用 | | --- | --- | --- | --- | --- | --- | | 担保方 | 被担保方 | 计担保额 | 计担保额 | 保余额 | 担保额度 | | | | 度 | 度 | （ 含 本 次 | （本次担保 | | | | | | 担保） | 后） | | 宁波天 益医疗 | TIANYI MEDICAL | | | ...

宁波天益医疗器械股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码： 301097 证券简称：天益医疗 公告编号：2026-002 重要内容提示： 1、回购股份的种类：宁波天益医疗器械股份有限公司（以下简称"公司"） 已发行的人民币普通股（A 股）股票。 2、回购股份的用途：用于实施股权激励或员工持股计划，若公司未能在股 份回购完成后的 36 个月内用于上述用途，未使用部分将予以注销。 3、回购价格：不超过人民币 65 元/股（含），该价格不高于公司董事会通 过回购决议前 30 个交易日公司股票交易均价的 150%。 （2）若对公司股票交易价格产生重大影响的重大事项发生，则存在回购方 案无法顺利实施的风险； （3）若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素 影响，致使公司不符合法律法规规定的回购股份条件，可能存在回购方案无法实 施的风险； （4）本次回购股份将用于后期实施股权激励或者员工持股计划，若公司未 能实施上述用途，未使用部分将依法注销，存在债权人要求公司提前清偿债务或 要求公司提供相应担 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2026-001 宁波天益医疗器械股份有限公司(以下简称"公司")第四届董事会第二次会 议通知于 2026 年 1 月 9 日以电话、短信、电子邮件等方式向公司全体董事发出。 会议于 2026 年 1 月 12 日上午 9:00 在公司会议室召开。 本次会议应参会董事 7 名，实际参会董事 7 名，其中董事江厚佳先生以通讯 方式参会。会议由董事长吴志敏先生召集和主持，部分高管列席了会议。本次会 议的召集、召开及表决程序符合有关法律、行政法规、部门规章、规范性文件及 《公司章程》的规定。 二、董事会会议审议情况 经与会董事审议表决，一致通过如下议案： 1、审议通过了《关于回购公司股份方案的议案》 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 宁波天益医疗器械股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 表决结果：7 票同 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2026-003 宁波天益医疗器械股份有限公司 回购报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、宁波天益医疗器械股份有限公司（以下简称公司）拟使用自有资金及银 行贷款以集中竞价交易方式回购公司部分人民币普通股（A 股）股票，用于实施 股权激励或员工持股计划。本次回购价格不超过人民币 65 元/股（含），回购资 金总额不低于人民币 6,000 万元（含），且不超过人民币 12,000 万元（含）。按 照回购股份价格上限和回购金额上下限测算，预计回购股份数量为 92.3077 万股 至 184.6154 万股，占公司目前总股本比例为 1.57%至 3.13%。具体回购股份的数 量以回购期限届满时实际回购的股份数量为准。回购期限自公司董事会审议通过 本次回购股份方案之日起不超过 12 个月。如国家对相关政策做调整，则本回购 方案按调整后的政策实行。 2、公司于 2026 年 1 月 12 日召开第四届董事会第二次会议，审议通过了《关 于回购公司股份方案的议案》。根据《上市公司股份 ...

Group 1: Climate Disclosure Standards - The Ministry of Finance, along with nine other departments, issued the "Corporate Sustainable Disclosure Standard No. 1 - Climate (Trial)" on December 25, marking a significant step towards a unified sustainable disclosure standard system in China [1] - The "Climate Standard" is currently positioned as a trial document, with voluntary implementation by companies until specific requirements are established [1] - The Ministry of Finance plans to adopt a gradual approach to implementation, expanding from listed companies to non-listed companies, and from large enterprises to small and medium-sized enterprises [1] Group 2: ESG Disclosure in A-Share Banks - The A-share ESG strong disclosure list has expanded to 27 banks, including 6 state-owned banks, 9 joint-stock banks, 10 city commercial banks, and 2 rural commercial banks [2] - Among the 27 banks, 16 reported a year-on-year decrease in carbon emissions, while 9 banks, including 1 state-owned bank and 6 city commercial banks, reported an increase in carbon emissions [2] - The top five banks with the highest year-on-year increase in carbon emissions are Beijing Bank (13.88%), Nanjing Bank (13.23%), Qingdao Bank (11.92%), Chongqing Bank (10.96%), and Hangzhou Bank (10.02%) [3] Group 3: Regulatory Actions and Penalties - First Capital's subsidiary was fined 12.7358 million yuan for failing to diligently supervise a convertible bond project [4] - Jinghua Pharmaceutical's subsidiary was fined 500,000 yuan for environmental pollution, which is not expected to significantly impact the company's net profit for 2025 [5] - Tianyi Medical is facing a potential fine of 8.7852 million yuan for not producing medical devices according to registered technical requirements [6][7] Group 4: Energy Sector ESG Developments - The "National Energy Sustainable Development Index" was officially launched, achieving a cumulative return rate of 40% [8] - Five thermal power companies have been included in the ESG strong disclosure category, which will require them to improve ESG governance and reporting by 2026 [9] - A report evaluated the low-carbon transition performance of 33 thermal power companies, indicating significant disparities in transition progress and a slower development of non-fossil energy compared to national averages [9]

宁波天益医疗器械股份有限公司 关于更换保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国泰海通证券股份有限公司（以下简称"国泰海通"）作为宁波天益医疗器 械股份有限公司（以下简称"公司"）首次公开发行股票并在创业板上市项目（以 下简称"首次公开发行项目"、"该项目"）的保荐机构，指派沈一冲先生、栾 俊先生为该项目的持续督导保荐代表人，续督导期至 2025 年 12 月 31 日。 近日，公司收到国泰海通《国泰海通证券股份有限公司关于更换宁波天益医 疗器械股份有限公司持续督导保荐代表人的函》，原保荐代表人栾俊先生先生因 工作变动，无法继续从事对公司的持续督导工作，为保证持续督导工作的有序进 行，国泰海通决定委派保荐代表人黄振东先生接替栾俊先生继续履行持续督导工 作。（黄振东先生简历附后）。 证券代码：301097 证券简称：天益医疗 公告编号：2025-068 特此公告。 宁波天益医疗器械股份有限公司 董事会 2025 年 12 月 26 日 附件：黄振东先生简历 黄振东先生，硕士研究生、保荐代表人、注册会计师，曾参与毓恬冠佳 IPO、 莱赛激 ...

Core Viewpoint - Tianyi Medical, a manufacturer of blood purification consumables, faces administrative penalties from the Ningbo Market Supervision Administration for producing medical devices that do not comply with registered technical requirements, with total penalties amounting to approximately 14.0179 million yuan [1][2]. Group 1: Regulatory Actions - The Ningbo Market Supervision Administration issued an administrative penalty notice to Tianyi Medical for failing to produce blood purification devices according to registered technical specifications, which constitutes a violation of the Medical Device Supervision and Administration Regulations [1]. - The penalties include the confiscation of 7,170 sets of illegally produced medical devices, the confiscation of illegal gains amounting to 523.27 million yuan, and a fine of 878.52 million yuan [2]. Group 2: Company Overview - Tianyi Medical specializes in the research, production, and sales of medical polymer consumables in the fields of blood purification and ward care, with key products including blood purification devices, disposable venous and arterial puncture devices, and blood dialysis concentrates [2]. - For the first three quarters of 2025, Tianyi Medical reported a revenue of 387 million yuan, representing a year-on-year increase of 24.14%, and a net profit attributable to shareholders of 20.0941 million yuan, up 216.81% year-on-year [2]. Group 3: Operational Status - Tianyi Medical stated that the regulatory issues will not lead to a situation that triggers mandatory delisting, and the company's production and operations remain normal [3].

Core Viewpoint - Tianyi Medical (301097) experienced a decline in stock price, closing at 51.89 yuan on December 25, 2025, down 5.43% with a turnover rate of 6.49% and a trading volume of 18,800 hands, resulting in a transaction amount of 98.79 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Tianyi Medical reported a main revenue of 387 million yuan, an increase of 24.14% year-on-year [3] - The net profit attributable to shareholders reached 20.09 million yuan, up 216.81% year-on-year, while the net profit after deducting non-recurring gains and losses was 8.41 million yuan, soaring 762.11% year-on-year [3] - In Q3 2025, the company achieved a quarterly main revenue of 160 million yuan, a year-on-year increase of 48.03%, with a quarterly net profit of 10.61 million yuan, up 227.86% year-on-year [3] Group 2: Financing and Capital Flow - On December 25, 2025, Tianyi Medical had a net inflow of retail investor funds amounting to 4.88 million yuan, which accounted for 4.93% of the total transaction amount [1] - The financing data indicated a financing buy of 4.75 million yuan and a financing repayment of 4.31 million yuan, resulting in a net financing buy of 0.43 million yuan [2] - The total balance of financing and securities lending stood at 51.97 million yuan [2]